옵션 체인은 다양한 행사가격과 만기일에 대한 Silexion Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Silexion Therapeutics에 대한 시장 심리를 평가합니다..

Silexion Therapeutics (NASDAQ:SLXN) 주식, 옵션 체인

Silexion Therapeutics

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BBWI

SLXN

월요일(25일) 아침 미국 주식 선물이 상승하는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식 몇 가지는 다음과 같다. 배스앤바디웍스, 애질런트, 실렉시온, 우드워드 및 줌 비디오

월요일 주목해야 할 주식: 배스앤바디웍스, 애질런트, 실렉시온, 우드워드 및 줌 비디오

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

<p><strong>Visa, Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) reported its first-quarter financial results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/01/b43352419/visa-fiscal-first-quarter-2025-financial-results">details from the report.&nbsp;</a></p>
<p><strong>The Details:&nbsp;</strong>Visa reported quarterly earnings of&nbsp;$2.75&nbsp;per share, which beat the analyst consensus estimate of&nbsp;$2.66.&nbsp;Quarterly revenue came in at $9.51 billion,&nbsp;which beat the analyst consensus estimate of&nbsp;$9.34 billion&nbsp;and is an&nbsp;increase over sales of&nbsp;$8.63 billion&nbsp;from the same period last year.</p>
<ul>
<li>Payments volume increased 9% over the prior year on a constant-dollar basis.</li>
<li>Cross-border volume excluding transactions within Europe increased by 16% on a constant-dollar basis.</li>
<li>Total cross-border volume on a constant dollar basis increased by 16% in the quarter.</li>
<li>Total processed transactions, which represent transactions processed by Visa, were 63.8 billion, an 11% increase over the prior year.</li>
<li>Fiscal first quarter service revenue was $4.2 billion, an increase of 8% over the prior year.</li>
</ul>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says"><strong>64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001&nbsp;</strong></a></p>
<p class="has-text-align-left">&#8220;Visa&#8217;s strong first-quarter results reflected healthy spending during the holiday season and improving trends in payments volume, cross-border volume, and processed transactions growth. We delivered 10% net revenue growth, 8% GAAP EPS growth and 14% non-GAAP EPS growth. As we continue through 2025, we remain focused on serving our clients and innovating across our three growth levers — consumer payments, new flows and value-added services,&#8221; said <strong>Ryan McInerney</strong>, CEO of Visa.</p>
<p><strong>V Price Action:</strong> According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Visa shares are up 2.13% after-hours at $346 Thursday.  </p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details"><strong>Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</strong></a><strong>&nbsp;</strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Fintech news covering the emerging Financial Technology services sector

Fintech

After-Hours Center

Movers

Visa Shares Rise On Solid Q1 Results: Details

<p>Hilltop Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTH#NYSE">HTH</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.28 by 96.43 percent. This is a 25 percent increase over earnings of $0.44 per share from the same period last year.</p>


Earnings Beats

Hilltop Hldgs Q4 2024 GAAP EPS $0.55 Beats $0.28 Estimate

<p>JP Morgan  analyst Brian Essex   maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Neutral and raises the price target from $233 to $244.</p>


Price Target

Analyst Ratings

JP Morgan Maintains Neutral on IBM, Raises Price Target to $244

<p><strong>Atlassian Corp </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) reported financial results for the fiscal second quarter after the market close on Thursday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/25/01/b43352428/atlassian-announces-second-quarter-fiscal-year-2025-results">key details from the print</a>.</p>
<p><strong>Q2 Earnings:</strong> Atlassian reported second-quarter revenue of $1.29 billion, beating <a href="https://www.benzinga.com/calendars/earnings">analyst estimates</a> of $1.24 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported second-quarter adjusted earnings of 96 cents per share, beating analyst estimates of 76 cents per share.</p>
<p>Total revenue was up 21% year-over-year, while subscription revenue grew 30% year-over-year. Cash flow from operations came in at&nbsp;$352 million&nbsp;and free cash flow totaled&nbsp;$343 million&nbsp;in the&nbsp;second quarter.</p>
<p>Atlassian ended the quarter with $2.5 billion in cash, cash equivalents and marketable securities.</p>
<p>&#8220;The Atlassian System of Work is resonating with enterprises all over the globe, as business leaders increasingly turn to the Atlassian platform to help teams across their organization collaborate on the opportunities and challenges they face,&#8221; said <strong>Mike Cannon-Brookes</strong>, co-founder and CEO of Atlassian.</p>
<p>&#8220;By infusing AI throughout our world-class cloud platform, we&#8217;re empowering all teams to accelerate collaboration and unlock organizational knowledge, further enabling them to unleash their full potential.&#8221;</p>
<p><strong>Guidance:</strong>&nbsp;Atlassian expects third-quarter revenue to be in the range of $1.345 billion to $1.353 billion. Cloud revenue is expected to grow 23.5% in the third quarter, data center revenue is expected to grow 7% and marketplace and other revenue is expected to be approximately flat.</p>
<p>The company also raised its fiscal year 2025 revenue growth expectations to a range of 18.5% to 19%, up from a range of 16.5% to 17% at the end of the company&#8217;s fiscal first quarter. </p>
<p>Management will further discuss the quarter on a conference call with analysts and investors at 5 p.m. ET.</p>
<p><strong>TEAM Price Action:</strong> <a href="http://benzinga.com/quote/team" target="_blank" rel="noreferrer noopener">Atlassian shares</a> were up 16.13% after hours, trading at $310 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p><strong>Check This Out: </strong><br />     • <strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43348280/amazon-ai-powered-aws-boom-can-it-outshine-microsoft-azure">Amazon AI-Powered AWS Boom: Can It Outshine Microsoft Azure?</a></strong></p>
<p><em>Photo: Shutterstock.</em></p>


TEAM

Atlassian Q2 Earnings: Revenue Beat, EPS Beat, Strong Guidance, 'Infusing' AI And More

<p>The Q4 earnings report for <strong>First Business Finl Servs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) was released on Thursday, January 30, 2025 at 04:00 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>First Business Finl Servs beat estimated earnings by 13.0%, reporting an EPS of $1.43 versus an estimate of $1.26.</p>
<p>Revenue was up $4.52 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.05, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at First Business Finl Servs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.19</td>
<td>1.09</td>
<td>1.12</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.24</td>
<td>1.23</td>
<td>1.04</td>
<td>1.15</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>38.77M</td>
<td>37.25M</td>
<td>37.73M</td>
<td>37.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>38.07M</td>
<td>37.97M</td>
<td>36.28M</td>
<td>36.63M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for First Business Finl Servs <a href="https://www.benzinga.com/quote/FBIZ/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FBIZ

First Business Finl Servs Earnings Report: Q4 Overview

<p><strong>Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Bancorp beat estimated earnings by 2.0%, reporting an EPS of $1.15 versus an estimate of $1.13.</p>
<p>Revenue was up $2.14 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company missed on EPS by $0.08 in the previous quarter, leading to a 14.000000000000002% drop share price change the next day.</p>
<p>Here's a look at Bancorp's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.07</td>
<td>1.05</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.04</td>
<td>1.07</td>
<td>1.06</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>99.31M</td>
<td>96.41M</td>
<td>116.51M</td>
<td>90.65M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>93.73M</td>
<td>93.80M</td>
<td>94.42M</td>
<td>92.16M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Bancorp management provided guidance for FY 2025, expecting earnings between $5.25 and $5.25 per share.</p>
<p>To track all earnings releases for Bancorp <a href="https://www.benzinga.com/quote/TBBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TBBK

Bancorp: Q4 Earnings Insights

<p><strong>Standex International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) just disclosed its Q2 earnings on Thursday, January 30, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Standex International beat estimated earnings by 14.000000000000002%, reporting an EPS of $1.91 versus an estimate of $1.67.</p>
<p>Revenue was up $11.41 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 4.0% increase share price change the next day.</p>
<p>Here's a look at Standex International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.70</td>
<td>1.72</td>
<td>1.67</td>
<td>1.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.71</td>
<td>1.76</td>
<td>1.75</td>
<td>1.78</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>181.39M</td>
<td>181.29M</td>
<td>180.14M</td>
<td>182.52M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>170.46M</td>
<td>180.19M</td>
<td>177.27M</td>
<td>178.40M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Standex International <a href="https://www.benzinga.com/quote/SXI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Standex International Q2 Earnings

<p>The Q4 earnings report for <strong>Weyerhaeuser</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) was released on Thursday, January 30, 2025 at 04:11 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Weyerhaeuser beat estimated earnings by 56.99999999999999%, reporting an EPS of $0.11 versus an estimate of $0.07.</p>
<p>Revenue was down $66.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.04, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at Weyerhaeuser's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.01</td>
<td>0.21</td>
<td>0.15</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.05</td>
<td>0.21</td>
<td>0.16</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.68B</td>
<td>1.95B</td>
<td>1.85B</td>
<td>1.86B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.68B</td>
<td>1.94B</td>
<td>1.80B</td>
<td>1.77B</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for Weyerhaeuser <a href="https://www.benzinga.com/quote/WY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Weyerhaeuser Q4 Earnings Assessment

<p><strong>Canadian National Railway</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Canadian National Railway missed estimated earnings by -3.0%, reporting an EPS of $1.3 versus an estimate of $1.34.</p>
<p>Revenue was down $169.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Canadian National Railway's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.23</td>
<td>1.41</td>
<td>1.25</td>
<td>1.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.26</td>
<td>1.35</td>
<td>1.28</td>
<td>1.48</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.98B</td>
<td>3.21B</td>
<td>3.10B</td>
<td>3.23B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.01B</td>
<td>3.16B</td>
<td>3.15B</td>
<td>3.29B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Canadian National Railway management provided guidance for FY 2025, expecting earnings between $5.58 and $5.84 per share.</p>
<p>To track all earnings releases for Canadian National Railway <a href="https://www.benzinga.com/quote/CNI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Canadian National Railway Earnings Report: Q4 Overview

<p><strong>Eastman Chemical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Eastman Chemical beat estimated earnings by 19.0%, reporting an EPS of $1.87 versus an estimate of $1.57.</p>
<p>Revenue was up $38.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat on EPS by $0.12 which was followed by a 4.0% drop in the share price the next day.</p>
<p>Here's a look at Eastman Chemical's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.14</td>
<td>2.01</td>
<td>1.43</td>
<td>1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.15</td>
<td>1.61</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.38B</td>
<td>2.36B</td>
<td>2.29B</td>
<td>2.21B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.46B</td>
<td>2.36B</td>
<td>2.31B</td>
<td>2.21B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Eastman Chemical management provided guidance for FY 2025, expecting earnings between $8.0 and $8.75 per share.</p>
<p>To track all earnings releases for Eastman Chemical <a href="https://www.benzinga.com/quote/EMN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Eastman Chemical Q4

<p>The Q2 earnings report for <strong>Viavi Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) was released on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Viavi Solutions beat estimated earnings by 30.0%, reporting an EPS of $0.13 versus an estimate of $0.1.</p>
<p>Revenue was up $16.30 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company missed on EPS by $0.0 in the previous quarter, leading to a 7.000000000000001% increase share price change the next day.</p>
<p>Here's a look at Viavi Solutions's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>0.07</td>
<td>0.07</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.06</td>
<td>0.08</td>
<td>0.06</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>240.10M</td>
<td>250.82M</td>
<td>249.08M</td>
<td>251.00M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>238.20M</td>
<td>252.00M</td>
<td>246.00M</td>
<td>254.50M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Viavi Solutions management provided guidance for Q3 2025, expecting earnings between $0.1 and $0.13 per share.</p>
<p>To track all earnings releases for Viavi Solutions <a href="https://www.benzinga.com/quote/VIAV/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VIAV

Viavi Solutions Earnings Analysis: Q2 Recap

<p><strong>Arthur J. Gallagher</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) reported its Q4 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Arthur J. Gallagher beat estimated earnings by 5.0%, reporting an EPS of $2.13 versus an estimate of $2.03.</p>
<p>Revenue was up $284.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company missed on EPS by $0.01 which was followed by a 2.0% drop in the share price the next day.</p>
<p>Here's a look at Arthur J. Gallagher's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.27</td>
<td>2.24</td>
<td>3.41</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>2.26</td>
<td>3.49</td>
<td>1.85</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.78B</td>
<td>2.76B</td>
<td>3.18B</td>
<td>2.36B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.81B</td>
<td>2.77B</td>
<td>3.26B</td>
<td>2.43B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Arthur J. Gallagher <a href="https://www.benzinga.com/quote/AJG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Arthur J. Gallagher Q4

<p><strong>Adtalem Glb Education</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) reported its Q2 earnings results on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Adtalem Glb Education beat estimated earnings by 32.0%, reporting an EPS of $1.81 versus an estimate of $1.37.</p>
<p>Revenue was up $54.49 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company beat on EPS by $0.16 in the last quarter, resulting in a 10.0% increase share price change the following day.</p>
<p>Here's a look at Adtalem Glb Education's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.13</td>
<td>1.28</td>
<td>1.16</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.29</td>
<td>1.37</td>
<td>1.50</td>
<td>1.23</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>397.70M</td>
<td>398.63M</td>
<td>391.70M</td>
<td>372.79M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>417.40M</td>
<td>409.91M</td>
<td>412.66M</td>
<td>393.24M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Adtalem Glb Education management provided guidance for FY 2025, expecting earnings between $6.1 and $6.3 per share.</p>
<p>To track all earnings releases for Adtalem Glb Education <a href="https://www.benzinga.com/quote/ATGE/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Adtalem Global Education Inc. Common Stock

ATGE

Recap: Adtalem Glb Education Q2 Earnings

<p>The earnings results for <strong>United States Steel</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) for Q4 were made public on Thursday, January 30, 2025 at 04:17 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>United States Steel missed estimated earnings by 0.0%, reporting an EPS of $-0.13 versus an estimate of $-0.13.</p>
<p>Revenue was down $635.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>During the previous quarter, the company beat on EPS by $0.09, leading to a 1.0% drop share price change the next day.</p>
<p>Here's a look at United States Steel's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.47</td>
<td>0.77</td>
<td>0.82</td>
<td>0.26</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.56</td>
<td>0.84</td>
<td>0.82</td>
<td>0.67</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.77B</td>
<td>4.02B</td>
<td>4.21B</td>
<td>3.76B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.85B</td>
<td>4.12B</td>
<td>4.16B</td>
<td>4.14B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for United States Steel <a href="https://www.benzinga.com/quote/X/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


United States Steel Q4 Earnings Assessment

<p>The Q3 earnings report for <strong>Boot Barn Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) was released on Thursday, January 30, 2025 at 04:10 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Boot Barn Holdings beat estimated earnings by 2.0%, reporting an EPS of $2.43 versus an estimate of $2.38.</p>
<p>Revenue was up $87.77 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company missed on EPS by $0.0 in the previous quarter, leading to a 20.0% drop share price change the next day.</p>
<p>Here's a look at Boot Barn Holdings's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.95</td>
<td>1.02</td>
<td>0.88</td>
<td>1.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.95</td>
<td>1.26</td>
<td>0.91</td>
<td>1.81</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>423.30M</td>
<td>411.38M</td>
<td>384.89M</td>
<td>521.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>425.80M</td>
<td>423.39M</td>
<td>388.46M</td>
<td>520.40M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Boot Barn Holdings management provided guidance for FY 2025, expecting earnings between $5.81 and $5.9 per share.</p>
<p>To track all earnings releases for Boot Barn Holdings <a href="https://www.benzinga.com/quote/BOOT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BOOT

Boot Barn Holdings Earnings Review: Q3 Summary

<p>Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 20 years by 6.82% on an annualized basis producing an average annual return of 15.24%. Currently, Union Pacific has a market capitalization of $151.52 billion. </p>
<p><strong>Buying $1000 In UNP:</strong> If an investor had bought $1000 of UNP stock 20 years ago, it would be worth <strong>$16,943.73</strong> today based on a price of $249.92 for UNP at the time of writing.</p>
<h3>Union Pacific's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738273510_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

<p><strong>PennyMac Mortgage IT</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) released its Q4 earnings on Thursday, January 30, 2025 at 04:15 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>PennyMac Mortgage IT beat estimated earnings by 11.0%, reporting an EPS of $0.41 versus an estimate of $0.37.</p>
<p>Revenue was up $23.15 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 1.0% drop in the share price the next day.</p>
<p>Here's a look at PennyMac Mortgage IT's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.36</td>
<td>0.35</td>
<td>0.32</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.17</td>
<td>0.39</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>90.91M</td>
<td>91.21M</td>
<td>85.37M</td>
<td>97.10M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>80.86M</td>
<td>71.20M</td>
<td>74.20M</td>
<td>84.77M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for PennyMac Mortgage IT <a href="https://www.benzinga.com/quote/PMT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PennyMac Mortgage IT Earnings Analysis: Q4 Recap

<p>Later adapted as a film, &#8220;The Big Short,&#8221; <strong>Michael Lewis</strong>&#8216; seminal book about the hedge funds that shorted the U.S. housing market before its eventual crash in 2008, shot several Wall Street pros to stardom. Among them were <strong>Porter Collins</strong>, <strong>Steve Eisman</strong>, <strong>Vincent Daniel</strong> and <strong>Danny Moses</strong>, who shorted mortgage-backed debt at FrontPoint Partners.</p>
<p>While the four made a killing from a short position in 2008, the Big Short alums are now focused more on going long. The traders reunited this week at an alternative investments conference in Miami, <a href="https://www.bloomberg.com/news/articles/2025-01-30/-big-short-traders-reuniting-for-hedge-fund-week-are-going-long">according</a> to Bloomberg.</p>
<p>Collins, co-founder of <strong>Seawolf Capital LLC</strong>, said on the panel that he has continued his spirit of contrarianism by investing in Asian markets, where valuations are currently cheaper. Daniel holds similar sentiments, but his rationale is the expectation that the U.S. Dollar will weaken, which would benefit foreign assets.</p>
<p><strong>Michael Burry</strong>, the founder of the hedge fund Scion Capital, was also featured prominently in the book and portrayed by <strong>Christian Bale</strong> in the film. Burry has also been bullish on China for several quarters — per his latest 13f filing, Scion Capital&#8217;s largest position is <strong>Alibaba Group Holding Ltd &#8211; ADR </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>).</p>
<p>The <strong>iShares MSCI China ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>) tracks Chinese equities, which have traded cheaper than U.S. stocks for several years.</p>
<p>Moses is also looking at value in the market. The frequent CNBC guest likes gold, as reflected in the <strong>SPDR Gold Trust </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).</p>
<p>Eisman, a University of Pennsylvania alum, touted homebuilder stocks given the shortage of new homes in the U.S. and anticipated easing of Federal Reserve monetary policy.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43350879/sam-bankman-frieds-parents-seek-presidential-pardon-from-trump">Sam Bankman-Fried&#8217;s Parents Seek Presidential Pardon From Donald Trump</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Asia

Equities

Global

BABA

MCHI

'The Big Short' Goes Long: Men Who Predicted Housing Bubble Prefer Asian Stocks, Gold

<p>PennyMac Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.36 by 13.89 percent. This is a 6.82 percent decrease over earnings of $0.44 per share from the same period last year.  The company reported quarterly sales of $107.93 million which beat the analyst consensus estimate of $93.95 million by 14.88 percent.  This is a 27.31 percent increase over sales of $84.77 million the same period last year.</p>


PennyMac Mortgage Q4 2024 GAAP  EPS $0.41 Beats $0.36 Estimate, Sales $107.93M Beat $93.95M Estimate

<p>Jefferies  analyst Simon Thackray   assumes James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) from Hold to Buy.</p>


Initiation

Jefferies Assumes James Hardie Industries to Buy

Silexion Therapeutics (SLXN) announced new preclinical results demonstrating the synergistic efficacy of its proprietary second-generation siRNA ca...

Silexion Therapeutics announces new preclinical results for SIL-204

Silexion Therapeutics drops 18%, prices $5M share offering

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute t...

Silexion Therapeutics reports preclinical data for SIL-204

Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds

Silexion Therapeutics, Tonix Pharmaceuticals, and Trinity Biotech Plc. are the 3&nbsp;Penny Stocks&nbsp;to watch on January 30, 2025, based on&nbsp...

3 Penny Stocks to Watch Now, 1/30/25

In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with a p...

Silexion Therapeutics (SLXN) Gets a Buy from Maxim Group

ACCD

AGEN

AKRO

ALLK

ALTR

ALXO

ARLUF

AZTR

BDTX

BLMZ

CANF

CELH

COST

DELL

DXST

ERNA

ETNB

FBGL

FTNT

GLXZ

GMVHF

GTBP

IBIO

INKT

INTU

ISRG

ITCI

JSPR

KAPA

KURA

LPTX

MMYT

MNST

MSDL

MSFT

MSTR

MVRK

NFLX

NIPG

NLSP

NXST

ONCO

ORKT

PGHL

PHIO

QBTS

QLGN

RGTI

SIEGY

SLRX

SMPL

SNGX

SSNLF

TECX

TNXP

TOPP

TRIB

TSX:VG

TVGN

TWLO

Contracts

Press Releases

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Health Care

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Comments

Silexion Therapeutics

Silexion Therapeutics (SLXN) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌